The estimated Net Worth of Masatsune Okajima is at least $2.04 Million dollars as of 28 February 2019. Masatsune Okajima owns over 886,950 units of Medicinova Inc stock worth over $2,039,439 and over the last 17 years Masatsune sold MNOV stock worth over $0.
Sign up
Masatsune Okajima MNOV stock SEC Form 4 insiders trading
Masatsune has made over 3 trades of the Medicinova Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Masatsune exercised 886,950 units of MNOV stock worth $3,716,321 on 28 February 2019.
The largest trade Masatsune's ever made was exercising 886,950 units of Medicinova Inc stock on 28 February 2019 worth over $3,716,321. On average, Masatsune trades about 57,424 units every 26 days since 2008. As of 28 February 2019 Masatsune still owns at least 1,040,530 units of Medicinova Inc stock.
You can see the complete history of Masatsune Okajima stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Masatsune Okajima's mailing address?
Masatsune's mailing address filed with the SEC is 4350 LA JOLLA VILLAGE DRIVE, SUITE 950, , SAN DIEGO, CA, 92122.
Insiders trading at Medicinova Inc
Over the last 18 years, insiders at Medicinova Inc have traded over $200,908 worth of Medicinova Inc stock and bought 459,744 units worth $1,581,779 . The most active insiders traders include Jeff Himawan, Masatsune Okajima und Yuichi Iwaki. On average, Medicinova Inc executives and independent directors trade stock every 95 days with the average trade being worth of $74,094. The most recent stock trade was executed by Hideki Nagao on 28 November 2022, trading 6,754 units of MNOV stock currently worth $15,197.
What does Medicinova Inc's logo look like?
Complete history of Masatsune Okajima stock trades at Medicinova Inc
Medicinova Inc executives and stock owners
Medicinova Inc executives and other stock owners filed with the SEC include:
-
Yuichi Iwaki,
President, Chief Executive Officer, Director -
Kazuko Matsuda,
Chief Medical Officer, Director -
Geoffrey O'brien,
Vice President -
Dr. Yuichi Iwaki M.D., Ph.D.,
Co-Founder, Pres, CEO & Exec. Director -
Dr. Kazuko Matsuda M.D., M.P.H., MPH, Ph.D.,
Chief Medical Officer & Director -
Hideki Nagao,
Independent Director -
Carolyn Beaver,
Director -
Edward Stepanow,
Chief Financial Officer -
Jeffrey Himawan,
Independent Chairman of the Board -
John O'Neil CPA,
Controller -
Dr. David H. Crean Ph.D.,
Chief Bus. Officer -
Dr. Federico Gaeta Ph.D.,
Chief Scientific Officer -
Douglas G Paulin CPA, CPA,
Chief Financial Officer -
Yutaka Kobayashi,
Director -
Yoshio Ishizaka,
Director -
Masatsune Okajima,
VP and Head of Japanese Office -
Federico C.A. Gaeta,
Chief Scientific Officer -
Tatsuo Izumi,
Director -
Den Boom Esther Van,
Chief Financial Officer -
Jeff Himawan,
Director -
John K A Prendergast,
Director -
Hiroaki Shigeta,
Director -
Kirk William Johnson,
Chief Scientific Officer -
Arlene Morris,
Director -
Michael Denis Coffee,
Chief Business Officer -
David D O'toole,
Director -
Alan W Dunton,
Director -
Shintaro Asako,
VP and Chief Financial Officer -
Richard E Sr Gammans,
Chief Development Officer -
Daniel Vapnek,
Director -
Kenneth W Locke,
Chief Scientific Officer -
Michael E Kalafer,
Chief Medical Officer -
Nicole Lemerond,
Director